Home›The Library›Gonadorelin
Gonadorelin
It was a real, FDA-approved drug once — Factrel for diagnostic testing, Lutrepulse for fertility induction — both withdrawn by their manufacturers for commercial reasons, not a safety finding. Today's off-label use, preserving fertility during testosterone therapy, has a plausible mechanism but not, as far as we could confirm, a dedicated randomized trial proving it works for that specific purpose.
On this page
In brief
Should you care? Yes, if you've heard it pitched as a fertility-safe alternative to HCG during testosterone therapy — it has a real approval history, but not for the use it's bought for now.The short version
- Genuinely approved twice, for pituitary diagnostic testing and pulsatile fertility induction — both discontinued.
- Withdrawn for commercial reasons, not an FDA safety finding, per consistent secondary reporting.
- No dedicated trial supports its current off-label TRT-adjacent use.
What it is, and its real approval history
Gonadorelin is synthetic GnRH. Factrel (Wyeth) was approved for diagnostic testing of pituitary gonadotroph function; Lutrepulse was approved for pulsatile induction of ovulation in women with hypothalamic amenorrhea, delivered via a dedicated pump. Both branded products were discontinued in the US by their manufacturers for commercial reasons rather than an FDA safety finding — consistently reported across pharmacy and clinical references, though unlike sermorelin's page, we did not locate the specific FDA Federal Register discontinuation notice for gonadorelin itself, so this should be read as well-supported by secondary sources rather than a directly quoted primary-source finding.
The real diagnostic evidence
The GnRH stimulation test — measuring LH/FSH response at set intervals after a dose — is a genuine, published diagnostic tool for distinguishing hypogonadotropic hypogonadism from constitutional delay of puberty. Worth noting precisely: much of the currently-cited diagnostic literature uses newer GnRH analogs like triptorelin rather than gonadorelin itself, a distinction that matters if you're trying to trace evidence back to this specific molecule.
Today's off-label use
Compounded gonadorelin is now widely used off-label in testosterone-therapy protocols to stimulate the testes directly, intended to preserve fertility and prevent testicular atrophy during treatment — a plausible, LH-receptor-mediated mechanism, and reportedly now more common for this purpose than HCG. We did not find a completed randomized trial establishing its efficacy for this specific off-label use.
What buyers should know
No FDA-approved gonadorelin product is currently marketed in the US. What's available is compounded, prescription-only, and used off-label for the TRT-adjacent purpose it's actually bought for today — not the diagnostic or fertility-induction uses it was originally approved for.
References
- Historical Factrel and Lutrepulse approval and discontinuation, as reported by RxList, Empower Pharmacy and other clinical/compounding-pharmacy references — no primary FDA discontinuation notice independently located for gonadorelin specifically.
- GnRH stimulation-test diagnostic literature — note that much of this research uses related GnRH analogs (e.g. triptorelin) rather than gonadorelin itself.